Labiotech.eu

Interview 22 Mar 2017

Watch a Partner at Spain’s Largest VC talk Investment Strategy

At BIO Europe Spring, we met Karen Wagner, a General Partner at Ysios, the VC dominating Spain’s investment scene. She told us what’s on the firm’s radar. Spain’s largest VC has positioned itself in Barcelona, having identified the city’s potential to be the next biotech hub in Europe. It has funded key biotechs in Spain, including Sanifit, which claimed the […]

March 22, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 22 Mar 2017

What’s the Gold Standard for Therapeutic Antibodies?

Are fully human antibodies the new gold standard in therapeutic innovation? If you want to upgrade, here’s where to find them. If you’re curious about the future of antibody development, look no further than Humira. This monoclonal antibody (mAb) for various inflammatory diseases soared to become the best-selling biological in 2016. Humira is a fully human […]

March 22, 2017 - 4 minutesmins - By External Contributor

News and Trends 21 Mar 2017

A Potential First Treatment for a Rare Genetic Disease clears Phase I

Minoryx Therapeutics has successfully completed a Phase I trial for its lead compound MIN-102 targeting X-linked adrenoleukodystrophy (X-ALD). The Spanish biotech Minoryx is specialized on orphan diseases and its lead program is a PPAR-gamma agonist, MIN-102, which is in development for X-ALD. The company now announced the successful results of its Phase I trial with MIN-102 revealing the […]

March 21, 2017 - 2 minutesmins - By Melanie De Almeida

More News! 21 Mar 2017

Better than Quantum Computing: The EU Launches a Biocomputer Project

The EU Horizon 2020 has launched Bio4Comp, a five-year €6.1M project to build more powerful and safer biocomputers that could outperform quantum computing. The Bio4Comp project has the ambitious goal of building a computer with greater processing speed and lower energy consumption than any of the most advanced computers existing today. Ultimately, this could translate into […]

March 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 21 Mar 2017

Rethinking Profits: Can a Socially Conscious Model work in Biotech?

As biopharma continues to weather a maelstrom of public scrutiny for its prices and profits, I asked executives about alternative models. Conventional wisdom in biotech is that the non-profit model can’t work in the industry: it takes a decade and billions in cash to develop a drug, with no guaranteed success. No investor would sink […]

March 21, 2017 - 7 minutesmins - By Evelyn Warner

C7XeJ78WkAEE Ic 1.jpg large e1490029653662

Interview 20 Mar 2017

Immuno-oncology is Overcrowded – Here is Where Startups Can Succeed

The unprecedented competition in the field represents a daunting challenge for companies trying to break in. A BIO-Europe Panel discussed remaining niches. BIO Europe’s panel on immuno-oncology was perhaps the most popular of the day, as attendees filled the room to hear the thoughts of John Haurum, CEO of F-star; Christophe Quéva, CSO of iTeos; and […]

March 20, 2017 - 3 minutesmins - By Evelyn Warner

Galecto Biotech BMS TD139 Phase Ia IIb 1

News and Trends 20 Mar 2017

Will BMS Take Over a Danish Biotech in a Massive €400M Deal?

Galecto Biotech has presented positive data from a Phase II study with its pulmonary fibrosis candidate, giving BMS the option of take over the biotech. In 2014, Denmark’s Galecto Biotech has signed an option agreement with US-based pharma Bristol-Myers Squibb (BMS) for its lead asset TD139, which is under development for the treatment of pulmonary […]

March 20, 2017 - 3 minutesmins - By Melanie De Almeida

More News! 20 Mar 2017

UPDATE: Swiss Medtech cancels IPO and goes for Record €411M Exit

UPDATE (10/04/2017): Symetis has decided to cancel its IPO following its acquisition by Boston Scientific in a €411M deal. The Swiss medtech company Symetis has launched a €55M IPO to accelerate the development of its next-generation heart valve replacement solutions. Symetis develops next-generation heart valve replacements for the treatment of cardiac valve conditions. With its […]

March 20, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 20 Mar 2017

French Biotech fails Second Phase II Trial for Cardiovascular Disease

Cerenis therapeutic’s lead candidate CER-001 has failed Phase II for the treatment of patients with post-acute coronary syndrome (ACS). The French-based Biotech Cerenis is developing therapies for the treatment of cardiovascular and metabolic diseases. The company now presented data on its lead candidate CER-001, which was investigated in a Phase II study for the treatment of patients with post-acute […]

March 20, 2017 - 3 minutesmins - By Melanie De Almeida

BenevolentAI Artificial Intelligence Fundraising

Interview 20 Mar 2017

Machines are Helping Healthcare: An Interview with their Biotech Leader

BenevolentAI is leading the charge in artificial intelligence. We talked to Jackie Hunter, who is the CEO of the company’s bioscience arm, BenevolentBio. Jackie Hunter has had quite an impressive career! After defending her PhD in psychology, she transitioned to GSK, where she clocked nearly 20 years in various leadership positions — Director while the […]

March 20, 2017 - 8 minutesmins - By Evelyn Warner

News and Trends 18 Mar 2017

Wellcome Image Awards: These are the Best Biology Images of the Year

The UK’s Wellcome trust has selected 22 pictures and images that capture the wonders of the life sciences. They’re now on exhibition in the UK and Ireland. The Wellcome Image Awards celebrates this year 20 years of bringing us the best biology images around the world. The awards are destined to visual masterpieces that communicate key aspects […]

March 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Circassia failure AstraZeneca deal cover

News and Trends 17 Mar 2017

Can this British Biotech Overcome Failure buying drugs from AstraZeneca?

After the big disaster with its cat allergy vaccine, Circassia closes a €214M deal to acquire rights from two AstraZeneca products for pulmonary disease. Circassia could not beat the placebo in a Phase III trial for cat allergy last year, which immediately drove its stock down by 65% and led to the halt of clinical […]

March 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Watch a Partner at Spain’s Largest VC talk Investment Strategy

What’s the Gold Standard for Therapeutic Antibodies?

A Potential First Treatment for a Rare Genetic Disease clears Phase I

Better than Quantum Computing: The EU Launches a Biocomputer Project

Rethinking Profits: Can a Socially Conscious Model work in Biotech?

Immuno-oncology is Overcrowded – Here is Where Startups Can Succeed

Will BMS Take Over a Danish Biotech in a Massive €400M Deal?

UPDATE: Swiss Medtech cancels IPO and goes for Record €411M Exit

French Biotech fails Second Phase II Trial for Cardiovascular Disease

Machines are Helping Healthcare: An Interview with their Biotech Leader

Wellcome Image Awards: These are the Best Biology Images of the Year

Can this British Biotech Overcome Failure buying drugs from AstraZeneca?

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!